Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
Incyte presented new data at the ESMO congress showing that its pancreatic cancer medicine, INCB161734, induces lasting tumor responses when combined with chemotherapy in patients with KRAS G12D-mutated pancreatic ductal adenocarcinoma. The company reported that these findings strengthen its late-stage gastrointestinal cancer programs. Incyte also views its position in the KRAS G12D pancreatic cancer drug race as neck and neck with competitor RevMed. These developments were showcased alongside other gastrointestinal portfolio highlights during the annual European Society for Medical Oncology meeting in Madrid.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Incyte announced that its pancreatic cancer medicine induces lasting tumor responses at the ESMO congress.
- ✓ Data for INCB161734 plus chemotherapy continues to elicit responses in KRAS G12D-mutated PDAC.
- ✓ Incyte considers itself neck and neck with RevMed in the KRAS G12D pancreatic cancer race.
- ✓ Incyte highlighted new data advancing its gastrointestinal cancer portfolio at ESMO 2026.
What changed
Incyte presented new clinical data at ESMO demonstrating lasting tumor responses for its INCB161734 pancreatic cancer combination therapy.
Live updates
-
Incyte Highlights KRAS G12D Data at ESMO
Incyte presented new data at the ESMO congress showing that its pancreatic cancer medicine, INCB161734, induces lasting tumor responses when combined with chemotherapy in patients with KRAS G12D-mutated pancreatic ductal adenocarcinoma. The company reported that these findings strengthen its late-stage gastrointestinal cancer programs. Incyte also views its position in the KRAS G12D pancreatic cancer drug race as neck and neck with competitor RevMed. These developments were showcased alongside other gastrointestinal portfolio highlights during the annual European Society for Medical Oncology meeting in Madrid.
Why it matters
The European Society for Medical Oncology congress serves as a major venue for pharmaceutical companies to present clinical updates on oncology pipelines. Incyte is competing in the specific therapeutic space targeting KRAS G12D mutations in pancreatic cancer. Understanding the performance of pipeline candidates like INCB161734 helps analysts gauge the competitive standing of drug developers in late-stage gastrointestinal cancer treatments.
What is confirmed
- Incyte announced that its pancreatic cancer medicine induces lasting tumor responses at the ESMO congress.
- Data for INCB161734 plus chemotherapy continues to elicit responses in KRAS G12D-mutated PDAC.
- Incyte considers itself neck and neck with RevMed in the KRAS G12D pancreatic cancer race.
- Incyte highlighted new data advancing its gastrointestinal cancer portfolio at ESMO 2026.
What to watch next
- Further clinical trial results for INCB161734 in late-stage gastrointestinal cancer programs
- Developments in the competitive race between Incyte and RevMed in KRAS G12D pancreatic cancer treatments
confidence 100%Sources used for this update (7)
- www.statnews.com — STAT — Reporting from the frontiers of health and medicine
- STAT — Incyte pancreatic cancer medicine induces lasting tumor responses, company says at ESMO
- Fierce Biotech — ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer race
- TradingView — INCY: Promising KRAS G12D and bispecific data strengthen late-stage GI cancer programs
- OncLive — INCB161734 Plus Chemotherapy Continues to Elicit Responses in KRAS G12D–Mutated PDAC
- Press Release Hub — Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026
- www.statnews.com — ESMO 2026: The STAT Recap
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community